相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase I study
David Khayat et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2013)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Philippe Rougier et al.
EUROPEAN JOURNAL OF CANCER (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
Ligia Traldi Macedo et al.
BMC CANCER (2012)
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
I. Diaz-Padilla et al.
BRITISH JOURNAL OF CANCER (2012)
A preclinical and clinical review of aflibercept for the management of cancer
Andrew Gaya et al.
CANCER TREATMENT REVIEWS (2012)
Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Nicolas Isambert et al.
CLINICAL CANCER RESEARCH (2012)
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
Patricia A. Tang et al.
CLINICAL CANCER RESEARCH (2012)
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
Rodryg Ramlau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
William P. Tew et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
A. Craig Lockhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Marja Lohela et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
Xiao-Feng Le et al.
CELL CYCLE (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer et al.
NATURE REVIEWS CANCER (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model
Henk M. W. Verheul et al.
CLINICAL CANCER RESEARCH (2007)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
LM Hu et al.
CLINICAL CANCER RESEARCH (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines
M Fukasawa et al.
CLINICAL CANCER RESEARCH (2004)
Molecular regulation of vessel maturation
RK Jain
NATURE MEDICINE (2003)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Vascular growth factors and lymphangiogenesis
L Jussila et al.
PHYSIOLOGICAL REVIEWS (2002)
分享论文
